Sirukumab: a promising therapy for rheumatoid arthritis

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Expert Opinion on Biological Therapy

• Publication date

  2017-04-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/14712598.2017.1315099PMID 28374627
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sarilumab for the treatment of rheumatoid arthritis.

  2016cited by this paper
• The changing landscape of biosimilars in rheumatology

  2016cited by this paper
• The Efficacy and Safety of Clazakizumab, an Anti–Interleukin‐6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis

  2016cited by this paper
• Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial.

  2016cited by this paper
• 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

  2016cited by this paper
• A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis

  2016cited by this paper
• A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective

  2016cited by this paper
• Emerging Therapies for Rheumatoid Arthritis

  2016cited by this paper
• Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.

  2016cited by this paper
• Rheumatoid arthritis

  2016cited by this paper
• Treating giant-cell arteritis: is IL-6 the cytokine to target?

  2016cited by this paper
• American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

  2015cited by this paper
• SAT0182 Improvement in Measures of Depressed Mood and Anhedonia, and Fatigue, In a Randomized, Placebo-Controlled, Phase 2 Study of Sirukumab, A Human Anti-Interleukin-6 Antibody, In Patients with Rheumatoid Arthritis

  2015cited by this paper
• Evaluation of Serum Interleukin‐6 Level as a Surrogate Marker of Synovial Inflammation and as a Factor of Structural Progression in Early Rheumatoid Arthritis: Results From a French National Multicenter Cohort

  2015cited by this paper
• Evaluation of disease‐mediated therapeutic protein–drug interactions between an anti–interleukin‐6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach

  2015cited by this paper
• Tocilizumab, A Humanized Anti-IL-6R Antibody, as an Emerging Therapeutic Option for Rheumatoid Arthritis: Molecular and Cellular Mechanistic Insights

  2015cited by this paper
• Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy

  2014influential reference
• Interleukin 6 and Rheumatoid Arthritis

  2014cited by this paper
• IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab

  2014cited by this paper
• RAPID3, an index of only 3 patient self-report core data set measures, but not ESR, recognizes incomplete responses to methotrexate in usual care of patients with rheumatoid arthritis.

  2013influential reference
• Pharmacokinetics and safety of sirukumab following a single subcutaneous administration to healthy Japanese and Caucasian subjects.

  2013cited by this paper
• Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.

  2013cited by this paper
• Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial

  2013cited by this paper
• Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.

  2013cited by this paper
• A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.

  2012cited by this paper
• The pro- and anti-inflammatory properties of the cytokine interleukin-6.

  2011cited by this paper
• Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.

  2011cited by this paper
• The Roles of Interleukin-6 in the Pathogenesis of Rheumatoid Arthritis

  2011cited by this paper
• A meta-analysis of cytokines in major depression.

  2010influential reference
• Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.

  2008cited by this paper
• Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II.

  2008cited by this paper
• The burden of musculoskeletal disease—a global perspective

  2006cited by this paper
• Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review.

  2006cited by this paper
• Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.

  2006cited by this paper
• A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate

  2004cited by this paper
• Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study.

  2002cited by this paper
• Muscle‐derived interleukin‐6: mechanisms for activation and possible biological roles

  2002cited by this paper
• Autostimulatory effects of IL‐6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL‐6 production and IL‐6R expression

  1992cited by this paper
• [Rheumatoid arthritis].

  1983cited by this paper

• Identification of potential hub genes and drugs in septic kidney injury: a bioinformatic analysis with preliminary experimental validation

  2025cites this paper
• Ginseng-Epimedii formula ameliorated experimental Sjögren’s syndrome via reducing IL-6 production

  2024cites this paper
• Interleukin 6 Inhibition in Rheumatoid Arthritis: Highlight on Olokizumab

  2023cites this paper
• New Targets and Strategies for Rheumatoid Arthritis: From Signal Transduction to Epigenetic Aspect

  2023cites this paper
• REVMATOİD ARTRİTİN MÜALİCƏSİNDƏ İL-6 ƏLEYHİNƏ MONOKLONAL ANTİCİSİMLƏRİN TƏTBİQİNİN PERSPEKTİVLƏRİ

  2022cites this paper
• Time to re-engage psychiatric drug discovery by strengthening confidence in preclinical psychopharmacology

  2021cites this paper
• Rheumatoid arthritis: Treatment evolution over the years

  2020cites this paper
• New era of therapy for endocrine autoimmune disorders

  2020cites this paper
• Anisodamine Maintains the Stability of Intervertebral Disc Tissue by Inhibiting the Senescence of Nucleus Pulposus Cells and Degradation of Extracellular Matrix via Interleukin-6/Janus Kinases/Signal Transducer and Activator of Transcription 3 Pathway

  2020cites this paper
• Secondary Analysis of Microarray Data Reveals Immune-Related Key Genes and Pathways in Chronic Spontaneous Urticaria

  2020cites this paper
• Integrated bioinformatics approach to understand immune-related key genes and pathways in chronic spontaneous urticaria

  2020cites this paper
• Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis

  2019cites this paper
• TCRM_A_167452 1073..1079

  2019cites this paper
• Corticosteroids as a cause of Catastrophic Rheumatoid Arthritis

  2019cites this paper
• Lupus, Silica, and Dietary Omega-3 Fatty Acid Interventions

  2019cites this paper
• Exposure‐Response Modeling Analyses for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin 6, in Patients With Moderately to Severely Active Rheumatoid Arthritis

  2018cites this paper
• Confirmatory Population Pharmacokinetic Analysis for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin‐6, in Patients With Moderately to Severely Active Rheumatoid Arthritis

  2018cites this paper
• Tocilizumab in the treatment of adult rheumatoid arthritis.

  2018cites this paper
• Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients

  2018cites this paper
• ABP 501 for the treatment of rheumatoid arthritis

  2018cites this paper
• JAK inhibitors: a promising direction for treating Rheumatoid Arthritis

  2017cites this paper